ZEVRA THERAPEUTICS, INC. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
On May 14–15, 2026, Zevra amended Timothy Sangiovanni's employment agreement (original date: February 1, 2017). The amendment modifies Section 4(E)(1)(d) to restrict accelerated vesting of equity awards upon termination without Cause or for Good Reason: awards granted on or after the amendment effective date are no longer eligible for automatic full acceleration and must instead vest per their individual award agreements. Awards granted before the amendment retain the prior full-acceleration provision. No dollar amounts, share counts, or performance metrics are disclosed.
Why this rating
Routine executive employment contract amendment reducing severance equity protection. No financial impact quantified; affects only forward-granted equity and is standard governance practice.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.